clinical hypothyroidism 4 and its potential risk, although still a matter of controversy 5, 6 of increased cardiovascular morbidity. In depressed subjects, subclinical hypothyroidism has been shown to be associated with a lower rate of response to antidepressants. 7, 8 There are limited studies on measurement of basal TSH levels in major depression. The relation to treatment response is unclear with several studies reporting favourable antidepressant response with either high-normal TSH 9, 10 or low-normal TSH. 11, 12 These studies are limited by small sample sizes, the definition of basal TSH groups, and treatment approach. [9] [10] [11] [12] Further, other studies reporting an inverse relation between basal TSH levels and severity of depression and measures of anxiety. 13, 14 There has been an ongoing debate in the thyroid literature about whether the normal range for TSH, usually from 0.5 to 5.0 mIU/L, may be too broad. [15] [16] [17] [18] It has been argued that the upper limit of normal should be reduced to 2.5 mIU/L to allow for identification of early thyroid failure 16, 18 given the limitations in how the normal range has been established. 18 The counter-argument for maintaining the current range for normal basal TSH levels is that TSH levels between 2.5 and 5.0 mIU/L have not been clearly established to increase morbidity associated with thyroid or other system disease. 17 As subclinical hypothyroidism has clearly been linked to poorer antidepressant response 7, 8 and the normal range for basal TSH in depressed subjects has been directly extrapolated from those established for normal populations, we examined the relation of ranges of basal TSH levels to clinical variables and treatment response in unipolar major depression, with a particular focus on the suggested new cut-off of 2.5 mIU/L.
Methods
Subjects for the study comprised 166 outpatients, aged between 18 and 65 years, attending the Mood Disorders program at the University of Toronto from 1991 onwards. All subjects fulfilled Research Diagnostic Criteria 19 for unipolar major depressive disorder based on interview with the SADS-L. 20 All subjects gave oral and written consent to participate in the study, which was approved by the Human Ethics Committee at the University of Toronto.
Subjects were medication-free at baseline and had not received lithium treatment for a minimum of 3 months. Subjects were excluded if they had a history of alcohol or substance abuse within the previous 3 months, any medical illness, or the use of concurrent medications, including oral contraceptives, which would affect their participation in the study, including the measurement of thyroid hormone levels. Patients were also excluded if they had been diagnosed with hypothyroidism or had had past thyroid surgery.
At baseline, subjects had a minimum score of 16 on the 17-item HDRS. 21 Blood was drawn for measurement by radioimmunoassay of T4, T3, TSH, and T3 resin uptake to allow for the calculation of Free Thyroxine Index. All subjects received open-label antidepressants, either tricyclics or SSRIs. An adequate trial was defined for SSRIs as a minimum dosage of fluoxetine of 20 mg/day (range of 20 to 60 mg/day), paroxetine of 20 mg/day (range of 20 to 60 mg/day), venlafaxine of 150 mg/day (range of 150 to 375 mg/day), or sertraline of 100 mg/day (range of 100 to 200 mg/day), and, for the tricyclic antidepressants (desipramine, imipramine, nortryptiline, or amitryptiline), as at least 2.5 mg/kg body weight/day and (or) if therapeutic blood levels were achieved. All medications were administered for 5 weeks, at which time the HDRS was repeated. Response to treatment was defined as a 50% or more reduction in HDRS scores between baseline and 5 weeks. All HDRS assessments were done by trained nurse raters blind to the thyroid function tests. Subsequently, subjects were treated according to physician preference, with a switch to alternate antidepressants or augmentation with lithium, T3, buspirone, or bupropion. At 3 months, the HDRS was readministered to assess treatment response.
Subjects were divided into 2 groups for the purposes of analysis: the low-normal TSH group (TSH = 0.5 to 2.5 mIU/L) and the high-normal TSH group (TSH = 2.6 to 5.0 mIU/L) in accordance with the aim of the study. The initial analysis involved a Student t test to determine if there was a significant difference in mean severity, using the HDRS, between the low-normal and high-normal TSH groups. Hotelling T was used with TSH group as the fixed categorical factor and symptom variables on the SADS-L as the independent variables. Separate Student t tests were used to examine for differences in each of the thyroid function tests between groups. Logistic regression with response as the categorical independent variable and several baseline demographic measures, including TSH group membership, as the independent variables were used to assess for factors (particularly TSH group) that might predict variance in treatment outcome. 
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Results
Among the 166 subjects, there were 54 men and 112 women. There was no significant difference in sex distribution between the low-normal TSH (women, 67.7%) and high-normal TSH (women, 66.6%) groups. The symptom severity scores associated with major depression that were derived from the SADS-L were then examined ( Table 2) . Using Hotelling T, there was an overall significant difference in these clinical variables between the 2 groups (T = 0.215, df = 18,147, P = 0.036). Subsequent post hoc univariate comparisons are reported in Table 2 . Of note, anxiety and insomnia scores were significantly higher in the low-normal TSH group, and there was a trend for suicidal tendencies to be higher in the same group.
Given the numerous comparisons with a moderate sample size (n = 166), we performed power calculations. For the difference in HDRS scores between the 2 groups, based on a = 0.05, df = 164 (N1 + N2 -2), and a SD 3.3 (the mean of the SDs of the 2 groups), and using a 2-sided test, the power was 0.7. For the MANOVA, the Mahalanobis distance was set at 0.4 (because items from the SADS-L are highly internally correlated), with a = 0.05 and a 2-sided test, the power was 0.6.
A comparison of response rates at week 5 and 12 between the TSH groups is shown in Table 3 . There was no significant difference in response rates at 5 or 12 weeks between the groups. When remission rates (a 50% or more reduction in the HDRS and a final score less than or equal to 7) were compared, there was no substantial difference in the findings.
Discussion
This study was prompted by the recent suggestion that the current normal range for basal TSH levels should be further truncated to an upper limit of 2.5 mIU/L, rather than 5.0 mIU/L, to identify milder cases of subclinical hypothyroidism. As subclinical hypothyroidism is associated with lower rates of antidepressant response, 7, 8 we examined clinical and treatment response correlates in patients with In our study, we found that the low-normal, compared with the high-normal, TSH group, were significantly more depressed, had significantly greater anxiety, and had a nonsignificant trend to more suicidal tendencies. This finding is consistent with previous studies; however, given the outcome data, the clinical significance of these findings is unclear. Moreover, the mean difference of about 1.5 on the 17-item HDRS between the groups would not indicate a substantial degree of clinical difference in severity of depression between the groups. However, the inverse relation between basal TSH and measures of depression severity is consistent with earlier studies showing a relation between illness severity and a blunted TRH test. Pathophysiological mechanisms for the blunted TRH response in acute depression remain speculative but may include higher circulating levels of T4, hypercortisolemia, or changes in body weight and nutritional status associated with the depression. We observed no difference in antidepressant response rates between the 2 groups. Our findings differ from other studies, which have found a relation between variations in normal basal TSH levels and antidepressant response. Both Corruble et al 11 and Gitlin et al 12 reported that higher TSH levels were associated with lower rates of response. However, Corruble and colleagues 11 included only 6 of 110 and 9 of 92 subjects, respectively, in each of their high TSH groups, and Gitlin et al 12 had a total sample of 19 in their open-label study. In contrast, Brouwer et al 10 found higher basal TSH levels associated with better response to paroxetine in 98 subjects. However, this study was designed to assess the efficacy of T3 addition to paroxetine using a placebo-controlled design. Although the authors claimed that T3 addition did not account for the finding of a relation between treatment Table 2 response and TSH levels, the aim and design of the study involving response to T3 appear to limit definitive conclusions about basal TSH levels and treatment response. Other studies find low basal TSH levels related to treatment response 9 or no relation at all. 22 Regardless of the methodological limitations, these studies did not specifically address differences in response between the upper and lower half of the conventional normal range for basal TSH levels.
Post hoc analyses of differences in clinical variables between low-and high-normal TSH groups
There are several limitations to our study. First, we treated patients in open-label fashion based on physician preference. Nonetheless, assessments of treatment outcome were made without knowledge of the results of the thyroid function tests. Second, initial treatment response was assessed at 5 weeks, which may be considered somewhat brief for an adequate antidepressant trial; however, a further assessment of response was obtained routinely at 12 weeks with consistent findings. Third, our power calculation reveals modest power, especially for the MANOVA. Therefore, our findings should be interpreted with caution and viewed as preliminary. In this regard, given the exploratory nature of our findings, we did not employ any post hoc tests for multiple comparisons. Future studies would require substantially larger samples to reduce the likelihood of a type I error. Last, it could be argued that use of the TRH test, that is, the TSH response to TRH, rather than basal TSH measurements, may yield more sensitive measures of thyroid function. This is a valid argument as the TRH test may reveal more subtle cases of subclinical hypothyroidism, although there is general agreement in the literature that, at least for clinical purposes, the TRH test provides limited additional information over later generation ultrasensitive TSH assays. 24 Our study suggests no difference in rates of treatment response between low-and high-normal TSH groups. Subclinical hypothyroidism and its relation to psychiatric illness still remains an issue of debate. 1, 23 The most robust finding to date is that subclinical hypothyroidism defined conventionally as a TSH level greater than 5.0 mIU/L is associated with lower rates of antidepressant response. 7, 8 Our study suggests that if the normal range of TSH is truncated to a range of 0.5 to 2.5 mIU/L, a further group of patients with major depression at risk for poorer antidepressant response may not necessarily be identified. Our findings, taken together with the literature, provide further impetus for research on the relation between subtle degrees of thyroid hypofunction and antidepressant response; although, currently, there is no clinical utility for using thyroid measures as predictors of antidepressant response.
Résumé : La thyrotropine basale et la dépression majeure : la relation aux variables cliniques et au résultat du traitement
Objectif : Une discussion a cours en thyroïdologie à savoir si l'écart normal de la thyrotropine basale (TSH) est trop étendu. Des groupes suggèrent qu'une TSH de moins de 2,5 mUI/L est un meilleur seuil d'inclusion pour l'euthyroïdisme. Parce que la dépression majeure est associée aux changements de l'état des hormones thyroïdiennes et que les hormones thyroïdiennes peuvent être un traitement efficace de la dépression majeure, nous avons examiné si les niveaux de la TSH inférieurs ou supérieurs à 2,5 mUI/L étaient reliés aux variables cliniques ou au résultat du traitement chez les patients euthyroïdiens souffrant de dépression majeure.
Méthodes : Des patients externes souffrant de dépression majeure (n =166) ont été affectés à des groupes de TSH normale faible et élevée, d'après leurs niveaux de TSH basale. Les 2 groupes ont été comparés en fonction des variables cliniques et du résultat du traitement.
Résultats : Le groupe de TSH normale faible était significativement plus déprimé, selon les scores obtenus à l'échelle de dépression de Hamilton, et avait plus de symptômes d'anxiété et de tendances suicidaires que le groupe de TSH normale élevée. Il n'y avait pas de différence entre les 2 groupes quant à la réponse au traitement.
Conclusions :
Une comparaison des groupes de TSH basale normale faible et élevée souffrant de dépression majeure a révélé des différences significatives de la gravité et des symptômes de la dépression, mais aucune différence dans le résultat du traitement. Ces données sont préliminaires et exigent d'être reproduites dans un échantillon plus large.
